The State Key Laboratory of Organic-inorganic Composites, Beijing Laboratory of Biomedical Materials, Key Laboratory of Biomedical Materials of Natural Macromolecules (Ministry of Education), College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
Department of Urology, China-Japan Friendship Hospitals, Beijing, 100029, China.
Adv Mater. 2024 May;36(21):e2309655. doi: 10.1002/adma.202309655. Epub 2024 Apr 1.
Surgery is the standard treatment regimen for resectable colorectal cancer (CRC). However, it is very hard to completely remove all cancer cells in clinical practice, leading to the high recurrence rates of the disease. Moreover, the post-surgery tissue adhesion greatly prevents the possibility of reoperation, significantly limiting the long-term surviving of CRC patients. To overcome CRC recurrence and avoid the post-surgery tissue adhesion, this work develops a novel stimulator of interferon genes "STING" membrane based on the coaxial electrospinning technology and hyaluronic acid modification. A reactive oxygen species responsive prodrug of gambogic acid (GB) and a potent STING agonist (CDN) are coloaded in the core-shell structure of the membrane, which endows the loaded drug with sustained and sequential release patterns. The localized delivery of GB and CDN can selectively induce efficient immunogenic cell death of cancer cells and then evoke the systemic anticancer immunity by activating the Cyclic GMP-AMP (cGAMP) synthase/STING pathway. As-designed "STING" membrane not only safely prevents tumor recurrence through the synergistic chemoimmunotherapy but also efficiently avoids the post-surgery tissue adhesion, facilitating the clinical intervention of CRC.
手术是可切除结直肠癌(CRC)的标准治疗方案。然而,在临床实践中很难完全清除所有癌细胞,导致疾病复发率很高。此外,手术后的组织粘连极大地阻碍了再次手术的可能性,严重限制了 CRC 患者的长期生存。为了克服 CRC 的复发并避免手术后的组织粘连,本工作基于同轴静电纺丝技术和透明质酸修饰开发了一种新型干扰素基因“STING”膜刺激剂。一种新型的姜黄素前药(GB)和一种有效的 STING 激动剂(CDN)共装载在膜的核壳结构中,使负载药物具有持续和顺序释放模式。GB 和 CDN 的局部递送可以选择性地诱导癌细胞有效的免疫原性细胞死亡,然后通过激活环鸟苷酸-腺苷酸(cGAMP)合酶/STING 途径引发全身性抗癌免疫。设计的“STING”膜不仅通过协同化免疫治疗安全地防止肿瘤复发,而且还能有效地避免手术后的组织粘连,为 CRC 的临床干预提供了便利。